Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.52 |
| ▸ | MGAM | O43451 | 14/20 | 0.49 |
| ▸ | GAA | P10253 | 14/20 | 0.49 |
| ▸ | SI | P14410 | 14/20 | 0.49 |
| ▸ | MGAM2 | Q2M2H8 | 14/20 | 0.49 |
| ▸ | ATP4A | P20648 | 1/20 | 0.46 |
| ▸ | ATP4B | P51164 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | CBFB | Q13951 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6139625 | 0.87 | MGAM (0.60) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL6509112 | 0.76 | CD44 (0.52) | CD44ATP4AATP4BALDH1A1TDP1 | |
| SCHEMBL727228 | 0.73 | MGAM (0.53) | MGAMGAASIMGAM2ATP4A | |
| Hydrogen Peroxide SCHEMBL14358429 | 0.72 | CD44 (0.90) | CD44ALDH1A1TDP1 | |
| Methyl Alcohol SCHEMBL28133981 | 0.72 | CD44 (0.90) | CD44ALDH1A1TDP1 | |
| SCHEMBL29363854 | 0.72 | — | — | |
| SCHEMBL27995928 | 0.72 | CD44 (1.00) | CD44ALDH1A1TDP1 | |
| SCHEMBL42498 | 0.72 | — | — | |
| SCHEMBL6999051 | 0.71 | CHEK1 (0.56) | MGAMGAASIMGAM2ATP4A | |
| Hydrogen Sulfide SCHEMBL28874707 | 0.70 | CD44 (0.94) | CD44ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032779-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032779-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | CBR3, CYP3A7, HDAC7 | CD44 3537/4885MGAM 4731/4885GAA 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.